{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:15Z","timestamp":1790727435397,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40618-020-01341-2","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T01:02:41Z","timestamp":1593046961000},"page":"1759-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves\u2019 Disease: results of a pilot study"],"prefix":"10.1007","volume":"43","author":[{"given":"G.","family":"Lanzolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nicol\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brancatella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mantuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Dottore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-116X","authenticated-orcid":false,"given":"M.","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"1341_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves' Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association\/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"1341_CR2","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest 36:444\u2013449","journal-title":"J Endocrinol Invest"},{"key":"1341_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40618-019-1010-9","volume":"42","author":"TT Shi","year":"2019","unstructured":"Shi TT, Xin Z, Hua L, Zhao RX, Yang YL, Wang H, Zhang S, Liu W, Xie RR (2019) Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study. J Endocrinol Invest 42:967\u2013978","journal-title":"J Endocrinol Invest"},{"key":"1341_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/thy.2014.0475","volume":"25","author":"M Leo","year":"2015","unstructured":"Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Role of the underlying thyroid disease on the phenotype of Graves\u2019 orbitopathy in a tertiary referral center. Thyroid 25:347\u2013351","journal-title":"Thyroid"},{"key":"1341_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current Insights into the pathogenesis of Graves' ophthalmopathy. Horm Metab Res 47:773\u2013778","journal-title":"Horm Metab Res"},{"key":"1341_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40618-019-01141-3","volume":"43","author":"M Marin\u00f2","year":"2020","unstructured":"Marin\u00f2 M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R, Marcocci C (2020) Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest 43:401\u2013411","journal-title":"J Endocrinol Invest"},{"key":"1341_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40618-018-0945-6","volume":"41","author":"S Seo","year":"2018","unstructured":"Seo S, S\u00e1nchez Robledo M (2018) Usefulness of TSH receptor antibodies as biomarkers for Graves\u2019 Ophthalmopathy: a systematic review. J Endocrinol Invest 41:1457\u20131468","journal-title":"J Endocrinol Invest"},{"key":"1341_CR8","doi-asserted-by":"publisher","first-page":"T29","DOI":"10.1530\/JME-17-0276","volume":"61","author":"M Mohyi","year":"2018","unstructured":"Mohyi M, Smith TJ (2018) IGF-I receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol 61:T29\u2013T43","journal-title":"J Mol Endocrinol"},{"key":"1341_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","volume":"26","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Heged\u00fcs L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab 26:291\u2013302","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1341_CR10","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 181:4397\u20134405","journal-title":"J Immunol"},{"key":"1341_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/thy.2007.0404","volume":"18","author":"TJ Smith","year":"2008","unstructured":"Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG (2008) Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18:983\u2013988","journal-title":"Thyroid"},{"key":"1341_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08916939309014643","volume":"16","author":"DR Weightman","year":"1993","unstructured":"Weightman DR, Perros P, Sherif IH, Kendall-Taylor P (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16:251\u2013577","journal-title":"Autoimmunity"},{"key":"1341_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","volume":"168","author":"J Pritchard","year":"2002","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ (2002) Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942\u2013950","journal-title":"J Immunol"},{"key":"1341_CR14","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348\u20136354","journal-title":"J Immunol"},{"key":"1341_CR15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"key":"1341_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352","journal-title":"N Engl J Med"},{"key":"1341_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1210\/jc.2012-1771","volume":"98","author":"WB Minich","year":"2013","unstructured":"Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, K\u00f6hrle J, Eckstein A, Schomburg L (2013) Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab 98:752\u2013760","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR18","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/jc.2011-0307","volume":"96","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM (2011) Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96:2386\u20132394","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/thy.2017.0105","volume":"27","author":"CC Krieger","year":"2017","unstructured":"Krieger CC, Neumann S, Marcus-Samuels B, Gershengorn MC (2017) TSHR\/IGF-1R Cross-Talk, Not IGF-1R stimulating antibodies, mediates Graves' ophthalmopathy pathogenesis. Thyroid 27:746\u2013747","journal-title":"Thyroid"},{"key":"1341_CR20","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2017.0281","volume":"27","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Janssen JA (2017) Response to Krieger et al. re: \u201cTSHR\/IGF-1R Cross-Talk, Not IGF-1R stimulating antibodies, Mediates Graves\u2019 Ophthalmopathy Pathogenesis\u201d (Thyroid 2017;27:746\u2013747). Thyroid 27:1458\u20131459","journal-title":"Thyroid"},{"key":"1341_CR21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1089\/thy.2017.0472","volume":"27","author":"S Neumann","year":"2017","unstructured":"Neumann S, Gershengorn MC (2017) Rebuttal to Smith and Janssen (Thyroid 2017;27:746\u2013747. DOI: 10.1089\/thy.2017.0281). Thyroid 27:1459\u20131460","journal-title":"Thyroid"},{"key":"1341_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/thy.2018.0089","volume":"28","author":"B Marcus-Samuels","year":"2018","unstructured":"Marcus-Samuels B, Krieger CC, Boutin A, Kahaly G, Neumann S, Gershengorn MC (2018) Evidence that Graves' ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors. Thyroid 28:650\u2013655","journal-title":"Thyroid"},{"key":"1341_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1210\/jc.2012-2270","volume":"98","author":"AJ Varewijck","year":"2013","unstructured":"Varewijck AJ, Boelen A, Lamberts SW, Fliers E, Hofland LJ, Wiersinga WM, Janssen JA (2013) Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 98:769\u2013776","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR24","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH\/IGF-1 receptor cross talk in Graves' ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340\u20132347","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","volume":"42","author":"M Marin\u00f2","year":"2019","unstructured":"Marin\u00f2 M, Rotondo Dottore G, Ionni I, Lanzolla G, Sabini E, Ricci D, Sframeli A, Mazzi B, Menconi F, Latrofa F, Vitti P, Marcocci C, Chiovato L (2019) Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy. J Endocrinol Invest 42:471\u2013480","journal-title":"J Endocrinol Invest"},{"key":"1341_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40618-019-01015-8","volume":"42","author":"ML Tanda","year":"2019","unstructured":"Tanda ML, Piantanida E, Masiello E, Cusini C, Bartalena L (2019) Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy? Endocrinol Invest 42:351\u2013352","journal-title":"Endocrinol Invest"},{"key":"1341_CR27","first-page":"161","volume":"23","author":"MP Mourits","year":"2004","unstructured":"Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. Explor Study Orbit 23:161\u2013168","journal-title":"Explor Study Orbit"},{"key":"1341_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/thy.2012.0379","volume":"23","author":"MA Profilo","year":"2013","unstructured":"Profilo MA, Sisti E, Marcocci C, Vitti P, Pinchera A, Nardi M, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Rago T, Marin\u00f2 M (2013) Thyroid volume and severity of Graves' orbitopathy. Thyroid 23:97\u2013102","journal-title":"Thyroid"},{"key":"1341_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/thy.2006.0279","volume":"17","author":"H Bilen","year":"2007","unstructured":"Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525\u2013528","journal-title":"Thyroid"},{"key":"1341_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/OPX.0b013e3181890dc7","volume":"85","author":"MB Kashkouli","year":"2008","unstructured":"Kashkouli MB, Nojomi M, Parvaresh MM, Sanjari MS, Modarres M, Noorani MM (2008) Normal values of hertel exophthalmometry in children, teenagers, and adults from Tehran. Iran Optom Vis Sci 85:1012\u20131017","journal-title":"Iran Optom Vis Sci"},{"key":"1341_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/112067210801800201","volume":"18","author":"U Beden","year":"2008","unstructured":"Beden U, Ozarslan Y, Ozt\u00fcrk HE, S\u00f6nmez B, Erkan D, Oge I (2008) Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol 18:165\u2013171","journal-title":"Eur J Ophthalmol"},{"key":"1341_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1442-9071.2009.02087.x","volume":"37","author":"W Chan","year":"2009","unstructured":"Chan W, Madge SN, Senaratne T, Senanayake S, Edussuriya K, Selva D, Casson RJ (2009) Exophthalmometric values and their biometric correlates: the Kandy Eye Study. Clin Exp Ophthalmol 37:496\u2013502","journal-title":"Clin Exp Ophthalmol"},{"key":"1341_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01223-7","author":"ML Tanda","year":"2020","unstructured":"Tanda ML, Gallo D, Ippolito S, Bartalena L, Piantanida E (2020) Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-020-01223-7","journal-title":"J Endocrinol Invest"},{"key":"1341_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40618-017-0717-8","volume":"40","author":"E Piantanida","year":"2017","unstructured":"Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Invest 40:885\u2013887","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01341-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T23:09:13Z","timestamp":1624576153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01341-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01341-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedure performed in the study involving human participants were in accordance with the ethical standards of the Trust and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}